Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?

Asthma is a chronic inflammatory disorder of the airways that is a major global burden on both individuals and healthcare systems. Despite guideline-directed treatment, a significant proportion of patients with asthma do not achieve control. This review focuses on the potential use of long-acting an...

Full description

Bibliographic Details
Main Authors:	William W. Busse, Ronald Dahl, Christine Jenkins, Alvaro A. Cruz
Format:	Article
Language:	English
Published:	European Respiratory Society 2016-03-01
Series:	European Respiratory Review
Online Access:	http://err.ersjournals.com/content/25/139/54.full

Similar Items

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
by: Price D, et al.
Published: (2015-01-01)

Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry
by: Hiroyuki Sugawara, et al.
Published: (2024-08-01)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
by: Yamada H, et al.
Published: (2018-10-01)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
by: Mineo Katsumata, et al.
Published: (2022-05-01)

Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease
by: Paul W. Jones
Published: (2015-06-01)

NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease
by: Claus Vogelmeier, et al.
Published: (2011-06-01)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
by: D’Urzo AD, et al.
Published: (2018-04-01)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
by: Ora J, et al.
Published: (2020-12-01)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
by: Bateman ED, et al.
Published: (2018-05-01)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
by: Eung Gu Lee, et al.
Published: (2023-05-01)

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
by: Israel Silva Maia, et al.

Muscarinic Receptor Agonists and Antagonists
by: David R. Kelly, et al.
Published: (2001-02-01)

Long-acting muscarinic antagonist and long-acting β-agonist combination for the treatment of maintenance therapy–naïve patients with chronic obstructive pulmonary disease: a narrative review
by: Roland Buhl, et al.
Published: (2024-10-01)

The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro
by: Maria Gabriella Matera, et al.
Published: (2024-02-01)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
by: Rebordosa C, et al.
Published: (2022-08-01)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
by: Luigino Calzetta, et al.
Published: (2022-05-01)

Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression
by: Yuji Oba, et al.
Published: (2015-02-01)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01)

Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis
by: Max Schlueter, et al.
Published: (2016-04-01)

Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014-01-01)

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis
by: Hurst JR, et al.
Published: (2018-03-01)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
by: James F. Donohue, et al.
Published: (2020-05-01)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
by: Melissa H. Roberts, et al.
Published: (2019-12-01)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
by: Masato Muraki, et al.
Published: (2021-01-01)

Multitargeting nature of muscarinic orthosteric agonists and antagonists
by: Jaromir Myslivecek
Published: (2022-09-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England
by: Requena G, et al.
Published: (2022-08-01)

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combinations in COPD
by: Mohd Kashif Siddiqui, et al.
Published: (2019-12-01)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
by: Ulrik CS
Published: (2012-09-01)

Reslizumab as add-on therapy in patients with refractory asthma
by: J Christian Virchow, et al.
Published: (2020-09-01)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
by: Requena G, et al.
Published: (2023-03-01)

Muscarinic receptor signaling in the pathophysiology of asthma and COPD
by: Zaagsma Johan, et al.
Published: (2006-05-01)

Muscarinic Receptors and Their Antagonists in COPD: Anti-Inflammatory and Antiremodeling Effects
by: George Karakiulakis, et al.
Published: (2012-01-01)

Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
by: Mehmet Muhittin Yalçın, et al.
Published: (2024-10-01)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
by: Beth Hahn, et al.
Published: (2019-04-01)

Synthesis and binding affinity studies of muscarinic receptor antagonists related to dehydrohimbacine
by: Ling-Jie Gao, et al.
Published: (2003-02-01)

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review
by: Calzetta L, et al.
Published: (2021-02-01)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
by: Liao PA, et al.
Published: (2023-04-01)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
by: Singer D, et al.
Published: (2020-12-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
by: Giulia Scioscia, et al.
Published: (2020-03-01)